Big Law
BioNTech’s New American Acquisition Will Strengthen Its Cancer Therapy Expertise
BioNTech said it was acquiring a production site and a research and development platform from a subsidiary of U.S. biotech company Gilead to expand its footprint in north America and in novel cancer treatments.
The German biotech firm on Monday said it was buying a solid tumour neoantigen T-cell receptor therapy (TCR-Ts) R&D platform and a manufacturing plant in the city of Gaithersburg in the state of Maryland from Kite Pharma.
T-cell receptors (TCRs) are a class of compounds that make it easier for the body’s immune cells to identify and destroy cancer cells, while TCR-Ts detect targets both inside and outside the cancer cells.
